Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2016

View Archived Issues

Sumitomo Dainippon Pharma reviews highlights of fourth quarter of fiscal 2015

Sanofi Genzyme and Johns Hopkins School of Medicine to collaborate on multiple sclerosis

REGENXBIO enters agreement with Biogen for gene therapy treatments against rare vision disorders

TopiVert finishes preclinical development of TOP-1630

Astellas reflects on milestones of fourth quarter of fiscal 2015

Infant Bacterial Therapeutics opens phase II trial of IBP-9414 to prevent necrotizing enterocolitis

Upsher-Smith Laboratories begins first clinical trial of USL-311

Inovio Pharmaceuticals' Zika vaccine shows promise in nonhuman primates

CDK9 inhibitor AZ-5576 is potent, selective and orally active

ME-401 well tolerated in healthy subjects, study in patients planned

Dong-A ST patents GDIR agonists

F. Hoffmann-La Roche discloses cytochrome P450 11B2 inhibitors

Redx Pharma describes antibacterial agents

RaQualia Pharma presents GHS receptor agonists

A1M Pharma initiates A1M-based research collaboration with CSL Behring

Shionogi develops AMPK activators

Cancer immunotherapy uses T cells expressing inducible MyD88/CD40 and targeted T-cell receptors

Bone Therapeutics reports results from phase I/II trial of ALLOB

European Commission approves Uptravi for pulmonary arterial hypertension

Eisai transfers ownership of AkaRx and worldwide rights to avatrombopag

FDA grants accelerated approval to nivolumab for patients with classical Hodgkin's lymphoma

Novo Nordisk submits BLA for nonacog beta pegol

Boehringer Ingelheim's olmunitib receives approval in South Korea

GVK Biosciences reports development of selective PI3Kbeta inhibitors

Onzetra Xsail launched in U.S.

Mabtech completes phase II/III study for STI-004

FDA grants orphan drug designation to VM-202 for ALS

New CDC7 inhibitor shows broad antitumor activity in vivo

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...